Latest Breaking News On - Klinische einheit - Page 1 : comparemela.com

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative thera.

United statesKlinische einheitJustine omalleyProtara therapeutics incExchange commissionGuggenheim securitiesCompany contactOppenheimer coPre funded warrantsCommon warrantsCommon warrantPre funded warrantAcorn bioventuresBoxer capitalWoodline partnersCatalio capital management

Protara Therapeutics Announces Positive Three-Month Data From TARA-002 Clinical Program In NMIBC

Protara Therapeutics Announces Positive Three-Month Data From TARA-002 Clinical Program In NMIBC
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesGautam jayramJustine omalleyJesse sheffermanKlinische einheitTimothy lyonDrug administrationTherapeutics centerClinical programUrology associatesProtara therapeutics incCompany contactUrology residency programExchange commissionChugai pharmaceutical co ltdNon muscle invasive bladder cancer

Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology

Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJesse sheffermanKlinische einheitCompany contactExchange commissionProtara therapeutics inc nasdaqDrug administrationMeeting of the society urologic oncologyProtara therapeutics incChugai pharmaceutical co ltdAnnual meetingUrologic oncologyChief executive officerBacillus calmette guNon muscle invasive bladder cancerRare pediatric disease designation

Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

Dosing is progressing well in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24Company init.

United statesJesse sheffermanKlinische einheitJustine omalleyExchange commissionProtara therapeutics incIv choline chloride programChugai pharmaceutical co ltdDrug administrationCompany contactProtara therapeutics inc nasdaqLymphatic malformationsChief executive officerBacillus calmette guOrphan drug designationRare pediatric disease designation

Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development

Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJathin bandariKlinische einheitProtara therapeutics inc nasdaqChugai pharmaceutical co ltdDrug administrationExchange commissionAmerican urological associationClinical development planCarolina urologic research centerCompany contactTherapeutics incNeal shoreMedical directorChief medical officerBacillus calmette gu